Table 5.
Risk of secondary primary malignancies based on age at the time of diagnosis of essential thrombocythemia
| SPM | Overall SIR (95%CI) | SIR for age group, 18-60 yr (95%CI) | SIR for age group, > 60 yr (95%CI) |
| All sites | 1.26 (1.09-1.45)1 | 1.78 (1.31-2.36)1 | 1.15 (0.98-1.35) |
| Solid tumors | 1.15 (0.98-1.35) | 1.75 (1.27-2.35)1 | 1.03 (0.85-1.23) |
| Colorectal | 0.66 (0.34-1.15) | 1.33 (0.27-3.88) | 0.56 (0.26-1.07) |
| Lungs/bronchus | 1.31 (0.89-1.86) | 2.36 (0.86-5.13) | 1.19 (0.77-1.75) |
| Breast | 1.06 (0.68-1.58) | 1.08 (0.40-2.35) | 1.06 (0.63-1.67) |
| Prostate | 1.11 (0.71-1.65) | 1.91 (0.82-3.76) | 0.92 (0.52-1.49) |
| Kidney | 2.40 (1.15-4.42)1 | 2.32 (0.28-8.37) | 2.42 (1.05-4.78)1 |
| Lymphoma | 1.59 (0.82-2.78) | 1.72 (0.21-6.23) | 1.57 (0.75-2.88) |
| Leukemia | 3.78 (2.2-6.05)1 | 3.74 (0.45-13.51) | 3.78 (2.12-6.24)1 |
| AML | 7.74 (3.71-14.24)1 | 12.73 (1.54-45.98)1 | 7.06 (3.05-13.90)1 |
1
Indicates a statistically significant value. AML: Acute myeloid leukemia; SIR: Standardized incidence ratio; SPM: Second primary malignancies.